Limin Zheng


Limin’s practice focuses on patent and other intellectual property and technology dispute resolution. She has over 15 years of hands-on experience in all stages of litigation, up to and including trial, involving a broad range of technologies. She has litigated in numerous forums, including federal courts, the International Trade Commission, and the Patent Trial and Appeal Board. She also has experience with patent litigation in China. In addition, Limin counsels clients on IP strategies and risk management, dispute avoidance, litigation strategy and management, and alternative dispute resolution, always with the same goal of finding the best solution for the client’s business objectives.

Before starting her legal career, Limin earned her Ph.D. in molecular, cellular and developmental biology from University of Pittsburgh. She conducted her postdoctoral research at Stanford University, School of Medicine, where she used genetic, biochemical, and cell biology methods to study intracellular trafficking and interactions of key molecules involved in early stages of animal development. With a deep technical background and extensive experience working with experts in patent litigations, Limin brings to bear her unique expertise in science-heavy and expert-intensive work.
A native of Shanghai, Limin is fluent in Mandarin Chinese.


  • Intellectual Property Litigation and Consulting, including patent, trademark, copyright, trade secrets, and inventorship disputes
  • Expert Evidence Litigation, including vetting and retaining experts, working with experts to explore and develop strong positions based on science, preparing and presenting experts for deposition and trial, and challenging the unreliable expert opinions
  • Patent Due Diligence and Landscape Evaluation, including patent validity and infringement analyses and freedom-to-operate counseling


  • Santa Clara County Bar Association
  • Asian Pacific American Bar Association of Silicon Valley
  • Asian American Bar Association of the Greater Bay Area
  • ChIPs Network
  • Guest columnist, Biosimilar Development
  • Mediation Panel, U.S. District Court for the Northern District of California


  • California Law Review, Senior Publishing Editor, 2002-2003
  • Berkeley Technology Law Journal, Annual Review Advisor, 2003
  • Fellow of the Jane Coffin Childs Memorial Fund for Medical Research


  • University of Pittsburgh, Ph.D., Molecular, Cellular, and Developmental Biology
  • The University of California, Berkeley School of Law, J.D.
    • While in law school, Limin served as a legal extern to the Honorable Claudia Wilken and the Honorable D. Lowell Jensen, United States District Court Judges with the Northern District of California.


  • California
  • U.S. District Courts for the Northern, Eastern, Central, and Southern Districts of California
  • U.S. District Court for the Eastern District of Texas
  • U.S. Court of Appeals for the Ninth Circuit
  • U.S. Court of Appeals for the Federal Circuit
  • U.S. Patent and Trademark Office


  • What Is Skinny Labeling – And Will It Work for Biosimilars?, Biosimilar Dev (Feb. 5, 2019)

  • How Will Trump’s New FTC/DOJ Reporting Requirements Impact Biosimilars?, Biosimilar Dev (Nov. 13, 2018)

  • A Biosimilar Applicant’s (Illusory?) Right To Declaratory Relief, Biosimilar Dev (Aug. 9, 2018)

  • Recent Supreme Court Decisions On Inter Partes Review — What Biosimilar Developers Need To Know, Bioprocess Online (May 22, 2018)

  • Shall We (Patent) Dance? — Key Considerations For Biosimilar Applicants, Biosimilar Dev (Feb. 27, 2018)

  • The Biosimilar Patent Dance: What Can We Learn From Recent BPCIA Litigation?, Biosimilar Dev (Mar. 6, 2018)

  • The Post-Mayo World Of Life Sciences Patents, Biosimilar Dev (December 2017 – January 2018)

  • The Biosimilar Patent Dance: When in Doubt, List It, Daily Journal (August 16, 2017)

  • What the Numbers Tell Us About the Section 101 ‘Fad’, Recorder (Mar. 2017)

  • Comment, Actual Innocence As a Gateway Through the Statute-of-Limitations Bar on the Filing of Federal Habeas Corpus Petitions, 90 CALIF. L. REV. 2101 (2002)

  • Note, Purdue Pharma L.P. v. Faulding Inc., 17 BERKELEY TECH. L.J. 95 (2002)


Intro to tech?
  • Running gel electrophoresis to separate and isolate DNA fragments
Favorite app?
  • Podcasts
  • While I generally prefer indoor activities (restaurants, movies, books) to outdoors, I do enjoy light gardening and casual walking (when it’s sunny and not too hot) with my husband.

Your Attorneys

David Miclean

Founder and Partner

Gary Gleason

Founder and Partner

Limin Zheng


This website Is designed for general Information only. The information presented at this site should not be construed to be formal legal advice nor the formation of a lawyer/client relationship.